CoChat

Surgical Technique for Subretinal Gene Therapy in Humans with Inherited Retinal Degeneration

Open access

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

The technique draws on personal experience with gene augmentation therapy by subretinal injection in patients with choroideremia, RPE65 mutation-associated retinal dystrophy, and X-linked retinitis pigmentosa. Only 2 surgeons initially performed RPE65 gene therapy in the Phase 3 clinical trial leading to drug approval in the United States and the European Union.1 As new surgeons begin to use the commercially available product voretigene neparvovec-rzyl for RPE65 mutation–related inherited retinal dystrophy (IRD) or to participate in clinical trials, there is a need for education in best practices for subretinal injection. Clinical trials are currently listed on clinicaltrials.gov for choroideremia,2–5 X-linked retinitis pigmentosa (RPGR genotype), autosomal recessive retinitis pigmentosa (MERTK genotype), achromatopsia (CNGA3 and CNGB3), Stargardt disease (ABCA4), Leber congenital amaurosis (CEP290), and Usher syndrome type 1B (MY07A), with several additional subretinal gene therapies in the pipeline. There are few options with currently available technology for delivery of gene therapy for IRD other than subretinal injection. Intravitreal injection of gene therapy is simpler to perform but is predicted to be useful only for optic nerve or retinal diseases affecting primarily the retinal nerve fiber layer, ganglion cell layers, and inner retinal layers (e.g., Leber hereditary optic neuropathy and X-linked retinoschisis RS1) due to barriers presented by the internal limiting membrane and the retinal tissue.6,7 Microcatheters advanced into suprachoroidal space of rabbits achieved transfection with adeno-associated virus 2 (AAV2) vector as demonstrated by GFAP expression8; however, there is concern that therapy delivered to the suprachoroidal space would be more difficult to target, require higher doses, be more likely to disseminate to unwanted systemic sites, or fail to penetrate outer blood retinal barrier at the level of the retinal pigment epithelium and Bruch membrane. Therefore, subretinal injection is likely to remain the procedure of choice for the near future. Technological innovations may facilitate surgical delivery of vector to the subretinal space.9–12 Although previous publications discuss surgical technique for gene therapy surgery, they do not provide a complete, surgeon-oriented surgical plan that is easy to follow in the operating room. The surgeon's manual for administration of voretigene neparvovec-rzyl intentionally gives general instructions with few details to allow for surgical discretion. The current protocol may help experienced vitreoretinal surgeons new to gene therapy adapt their own procedures and operating room setting to facilitate safe and efficient surgery. Surgical Protocol Our methods of subretinal injection were refined during multiple surgeries at Bascom Palmer Eye Institute involving patients enrolled in Phase II to III clinical trials, but also patients treated with commercial products. Many steps are routine best practice procedures for vitreoretinal surgery adapted to a comprehensive plan for gene therapy surgery. The interventions described here were approved by the Human Subjects Research Office of the University of Miami when they involved patients enrolled in clinical trials. All patients signed standard consents for surgery as required by our hospital. Patient Selection and Preparation Select candidates by phenotype. Use CLIA-certified genetic testing to confirm the pathogenic genetic variant. Document retinal function with visual acuity, visual fields, and electrophysiology; retinal anatomy with fundus photography, optical coherence tomography (OCT), and autofluorescence. Use microperimetry to assess the favored fixation point. Obtain informed consent emphasizing risks of subretinal surgery including blindness, decreased vision, scarring, disease progression, injury to surrounding structures, inflammation, macular hole, and retinal detachment. Gene therapy surgery now may limit access to future clinical trials. Consider pretreatment with oral corticosteroids at up to 1 mg/kg for 3 days with postoperative taper. Doses higher than 60 to 80 mg daily may increase the risk of systemic complications. Vector Preparation Order gene vector product with sufficient lead-time for surgery. Coordinate time of surgery with vector prep time to ensure injection is within the viable use period. Have pharmacists prepare the vector using sterile protective gear in a negative pressure room and biohazard hood or as specified by protocol. Inspect vector for signs of contamination and verify that it is the intended product for the patient. Note expiration time. Preparation for Surgery Supplemental Digital Content 1 (see Table, https://links.lww.com/IAE/B27) lists commonly used instruments and supplies. Review photographs. Assess target zone and proposed injection sites. Plan the injection site(s) to cover the target zone without overstretching the retina or exceeding the allowed volume

Overview

Integrity signals

Registry

Crossref · 10.1097/iae.0000000000002609

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Cited by

See all 74

Metadata

Authors
Davis, J. L., Gregori, N. Z., MacLaren, R. E., & Lam, B. L.
Affiliations
  • University of Miami (US)
  • University of Oxford (GB)
Corresponding author
  • Davis, Janet L.
  • Gregori, Ninel Z.
  • Lam, Byron L.
Venue
Retina
Published
2019-10
Volume
39
Issue
1
Pages
S2-S8
ISSN
0275-004X (ISSN-L)
OpenAlex
W2962807939
Cited by
72
References
19
Citations by year
2026: 5 · 2025: 14 · 2024: 9 · 2023: 13 · 2022: 3 · 2021: 17 · 2020: 10 · 2019: 1
FWCI
2.57
Type
journal article
Language
en
Open access
Locations
  • Retina (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
subretinal gene therapy, subretinal injection, surgical technique, inherited retinal degeneration, choroideremia, X-linked retinitis pigmentosa, adeno-associated virus vectors, suprachoroidal injection, surgical planning, retinal pigment epithelium
MeSH terms
Humans, Retina, Retinal Degeneration, Ophthalmologic Surgical Procedures, Genetic Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Surgical Technique for Subretinal Gene Therapy in Humans with Inherited Retinal Degeneration. https://app.cochat.ai/papers/10.1097/iae.0000000000002609
The paper
Davis, J. L., Gregori, N. Z., MacLaren, R. E., & Lam, B. L. (2019). Surgical Technique for Subretinal Gene Therapy in Humans with Inherited Retinal Degeneration. Retina. https://doi.org/10.1097/iae.0000000000002609

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.